Compare Novartis AG (NVS) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Schwab US Large Cap Growth ETF — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Schwab US Large Cap Growth ETF trades at $34.27. The key difference: Novartis AG pays a 3.17% dividend while Schwab US Large Cap Growth ETF pays none, and Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | SCHG | |
|---|---|---|
Market Cap | $290.25B | — |
Sector | Health | Sector/Thematic |
52-Week High | $168.62 | $35.30 |
52-Week Low | $113.50 | $28.10 |
Enterprise Value | $330.27B | — |
Dividend Yield | 3.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
SCHG trades at $34.15, down 0.09% on the day, with a neutral technical signal. The ETF offers concentrated exposure to U.S. large-cap growth stocks, particularly in technology and AI-driven sectors, with a low 0.04% expense ratio. Recent institutional buying includes a 7.3% position increase by Alpha Zero LLC (Defense World, July 21, 2026).
Outlook remains mixed; strong fundamentals and AI growth potential support long-term gains, but high concentration in top holdings and elevated valuations near 32x P/E pose risks. Market sentiment is divided between bullish growth prospects and concerns over reliance on mega-cap performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
